A randomized, placebo-controlled trial of aprotinin to reduce primary graft dysfunction following lung transplantation

Clinical Transplantation

Volumn 25, Issue 1, 2011, Pages 90-96

  Herrington, Cynthia S ^a   Prekker, Matthew E ^b   Arrington, Amanda K ^b   Susanto, Daniel ^b   Baltzell, Jim W ^b   Studenski, Leslie L ^b   Radosevich, David M ^b   Kelly, Rosemary F ^b   Shumway, Sara J ^b   Hertz, Marshall I ^b   Bittner, Hartmuth B ^c   Dahlberg, Peter S ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Aprotinin; Donor lung perfusion; Graft dysfunction; Lung transplant; PGD

Indexed keywords

APROTININ; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LUNG GRAFT DYSFUNCTION; LUNG PERFUSION; LUNG TRANSPLANTATION; MALE; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIMARY GRAFT DYSFUNCTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; APROTININ; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; KIDNEY FUNCTION TESTS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PRIMARY GRAFT DYSFUNCTION; PROSPECTIVE STUDIES; SERINE PROTEINASE INHIBITORS; SURVIVAL RATE; TISSUE DONORS; TREATMENT OUTCOME;

EID: 79551695426     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01319.x     Document Type: Article

References (24)

1. Arcasoy SM, Fisher A, Hachem RR, Scavuzo M, Ware LB. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part V: predictors and outcomes. J Heart Lung Transplant 2005: 24: 1483.
2. Christie JD, Kotloff RM, Ahya VN et al. The effect of primary graft dysfunction on survival after lung transplantation. Am J Respir Crit Care Med 2005: 171: 1312.
3. Christie JD, Bavaria JE, Palevsky HI et al. Primary graft failure following lung transplantation. Chest 1998: 114: 51.
4. Christie JD, Kotloff RM, Pochettino A et al. Clinical risk factors for primary graft failure following lung transplantation. Chest 2003: 124: 1232.
5. Dahlberg PS, Prekker ME, Hertz M, Thompson DJ, Park SJ. Recent trends in lung transplantation: the University of Minnesota experience. Clin Transplant 2002: 243.
6. Prekker ME, Nath DS, Walker AR et al. Validation of the proposed International Society for Heart and Lung Transplantation grading system for primary graft dysfunction after lung transplantation. J Heart Lung Transplant 2006: 25: 371-378.
7. Whitson BA, Nath DS, Johnson AC et al. Risk factors for primary graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg 2006: 131: 73.
8. De Perrot M, Lui M, Waddell TK, Keshavjee S. Ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med 2003: 167: 490.
9. Landis RC, Asimakopoulos G, Poullis M, Haskard DO, Taylor KM. The antithrombotic and anti-inflammatory mechanisms of action of aprotinin. Ann Thorac Surg 2001: 72: 2169.
10. Dahlberg PS, Prekker ME, Herrington CS, Mertz MI, Park SJ. Medium-term results of extracorporeal membrane oxygenation for severe acute lung injury after lung transplantation. J Heart Lung Transplant 2004: 23: 979.
11. Christie JD, Van Raemdonck D, De Perrot M et al. Report of the ISHLT working group on primary lung dysfunction part I: introduction and Methods. J Heart Lung Transplant 2005: 24: 1451.
12. Christie JD, Carby M, Bag R, Corris P, Mertz M, Well D. Report of the ISHLT working group on primary lung dysfunction part II: Definition A consensus statement for the International Society for Heart and Lund Transplantation. J Heart Lung Transplant 2005: 24: 1454.
13. De Perrot M, Bosner RS, Dark J et al. Report of the ISHLT working group on primary lung dysfunction part III: donor-related risk factors and markers. J Heart Lung Transplant 2005: 24: 1460.
14. Barr MI, Kawat SM, Whalen TP et al. Report of the ISHLT working group on primary lung dysfunction part IV: recipient-related risk factors and markers. J Heart Lung Transplant 2005: 24: 1468.
15. Shargall Y, Guenther G, Ahya VN, Ardehali A, Singhal A, Keshavjee S. Report of the ISHLT working group on primary lung dysfunction part VI: treatment. J Heart Lung Transplant 2005: 24: 1489.
16. Christie JD, Robinson N, Ware JB et al. Association of Protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction. Am J Respir Crit Care Med 2007: 175: 69.
17. Mangano DT, Tudor IC, Detzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006: 354: 353.
18. Mangano DT, Maio Y, Vulsteke A et al. Mortality associated with aprotinin during 5years following coronary artery bypass graft surgery. JAMA 2007: 297: 471.
19. Ferguson TB. Aprotinin - are there lessons learned? JAMA 2007: 297: 527.
20. Bittner HB, Binner C, Dahlberg P, Mohr FW. Reducing ischemia-reperfusion injury in clinical lung transplantation. Transplant Proc 2007: 39: 489.
21. ISHLT. 2006 Transplant Registry Quarterly Reports for Lung in North America Characteristics for Transplants performed between January 1, 2005 and June 30, 2006.
22. Shimoyama T, Tabuchi N, Kojima K et al. Aprotinin attenuated ischemia-reperfusion injury in an isolated rat lung model after 18hours preservation 2005. Eur J Cardiothorac Surg 2005: 28: 581.
23. Roberts RF, Nishanian GP, Carey JN et al. Addition of aprotinin to organ preservation solutions decreases lung reperfusion injury. Ann Thorac Surg 1998: 66: 225-30.
24. Bittner HB, Richter M, Kuntze T et al. Aprotinin decreases reperfusion injury and allograft dysfunction in clinical lung transplantation. Eur J Cardiothorac Surg 2006: 29: 210.